Phase 2/3 Illuminate trial results of sepofarsen in CEP290-mediated LCA10 News update Top-line results showed the Illuminate study did not meet its primary endpoint or secondary endpoints. We will continue to analyze the data. February 11, 2022
Conference call top-line results Phase 2/3 Illuminate trial Webcast ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10. February 11, 2022